Literature DB >> 29358170

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.

Pavithra Viswanath1, Marina Radoul1, Jose Luis Izquierdo-Garcia2,3, Wei Qiang Ong4, Hema Artee Luchman5, J Gregory Cairncross6, Bo Huang4, Russell O Pieper7, Joanna J Phillips7, Sabrina M Ronen8.   

Abstract

Tumor metabolism is reprogrammed to meet the demands of proliferating cancer cells. In particular, cancer cells upregulate synthesis of the membrane phospholipids phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdE) in order to allow for rapid membrane turnover. Nonetheless, we show here that, in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas, which produce the oncometabolite 2-hydroxyglutarate (2-HG), PtdCho and PtdE biosynthesis is downregulated and results in lower levels of both phospholipids when compared with wild-type IDH1 cells. 2-HG inhibited collagen-4-prolyl hydroxylase activity, leading to accumulation of misfolded procollagen-IV in the endoplasmic reticulum (ER) of both genetically engineered and patient-derived IDHmut glioma models. The resulting ER stress triggered increased expression of FAM134b, which mediated autophagic degradation of the ER (ER-phagy) and a reduction in the ER area. Because the ER is the site of phospholipid synthesis, ER-phagy led to reduced PtdCho and PtdE biosynthesis. Inhibition of ER-phagy via pharmacological or molecular approaches restored phospholipid biosynthesis in IDHmut glioma cells, triggered apoptotic cell death, inhibited tumor growth, and prolonged the survival of orthotopic IDHmut glioma-bearing mice, pointing to a potential therapeutic opportunity. Glioma patient biopsies also exhibited increased ER-phagy and downregulation of PtdCho and PtdE levels in IDHmut samples compared with wild-type, clinically validating our observations. Collectively, this study provides detailed and clinically relevant insights into the functional link between oncometabolite-driven ER-phagy and phospholipid biosynthesis in IDHmut gliomas.Significance: Downregulation of phospholipid biosynthesis via ER-phagy is essential for proliferation and clonogenicity of mutant IDH1 gliomas, a finding with immediate therapeutic implications. Cancer Res; 78(9); 2290-304. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29358170      PMCID: PMC5932252          DOI: 10.1158/0008-5472.CAN-17-2926

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Phospholipid biosynthesis in mammalian cells.

Authors:  Jean E Vance; Dennis E Vance
Journal:  Biochem Cell Biol       Date:  2004-02       Impact factor: 3.626

2.  Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action.

Authors:  T Sasaki; K Majamaa; J Uitto
Journal:  J Biol Chem       Date:  1987-07-05       Impact factor: 5.157

3.  Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery.

Authors:  Fiorenza Fumagalli; Julia Noack; Timothy J Bergmann; Eduardo Cebollero; Giorgia Brambilla Pisoni; Elisa Fasana; Ilaria Fregno; Carmela Galli; Marisa Loi; Tatiana Soldà; Rocco D'Antuono; Andrea Raimondi; Martin Jung; Armin Melnyk; Stefan Schorr; Anne Schreiber; Luca Simonelli; Luca Varani; Caroline Wilson-Zbinden; Oliver Zerbe; Kay Hofmann; Matthias Peter; Manfredo Quadroni; Richard Zimmermann; Maurizio Molinari
Journal:  Nat Cell Biol       Date:  2016-10-17       Impact factor: 28.824

4.  1H- and (31)P-MR spectroscopy of primary and recurrent human brain tumors in vitro: malignancy-characteristic profiles of water soluble and lipophilic spectral components.

Authors:  F G Lehnhardt; G Röhn; R I Ernestus; M Grüne; M Hoehn
Journal:  NMR Biomed       Date:  2001-08       Impact factor: 4.044

5.  IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Authors:  Morteza Esmaeili; Bob C Hamans; Anna C Navis; Remco van Horssen; Tone F Bathen; Ingrid S Gribbestad; William P Leenders; Arend Heerschap
Journal:  Cancer Res       Date:  2014-07-08       Impact factor: 12.701

6.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

7.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

8.  Autophagy and its effects: making sense of double-edged swords.

Authors:  Andrew Thorburn
Journal:  PLoS Biol       Date:  2014-10-14       Impact factor: 8.029

9.  Analysis of macroautophagy by immunohistochemistry.

Authors:  Mathias T Rosenfeldt; Colin Nixon; Emma Liu; Li Yen Mah; Kevin M Ryan
Journal:  Autophagy       Date:  2012-05-07       Impact factor: 16.016

10.  Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.

Authors:  Pavithra Viswanath; Chloe Najac; Jose L Izquierdo-Garcia; Aleksandr Pankov; Chibo Hong; Pia Eriksson; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Oncotarget       Date:  2016-06-07
View more
  21 in total

1.  Quercetin Might Promote Autophagy in a Middle Cerebral Artery Occlusion-Mediated Ischemia Model: Comments on Fawad-Ali Shah et al.

Authors:  Salvatore Chirumbolo; Antonio Vella; Geir Bjørklund
Journal:  Neurochem Res       Date:  2018-12-04       Impact factor: 3.996

Review 2.  Targeting Autophagy in Cancer: Recent Advances and Future Directions.

Authors:  Ravi K Amaravadi; Alec C Kimmelman; Jayanta Debnath
Journal:  Cancer Discov       Date:  2019-08-21       Impact factor: 39.397

3.  Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer.

Authors:  Georgios Batsios; Céline Taglang; Meryssa Tran; Nicholas Stevers; Carter Barger; Anne Marie Gillespie; Sabrina M Ronen; Joseph F Costello; Pavithra Viswanath
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

4.  Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.

Authors:  Céline Taglang; Georgios Batsios; Joydeep Mukherjee; Meryssa Tran; Anne Marie Gillespie; Donghyun Hong; Sabrina M Ronen; Hema Artee Luchman; Russell O Pieper; Pavithra Viswanath
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

5.  Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.

Authors:  Pavithra Viswanath; Georgios Batsios; Vinay Ayyappan; Céline Taglang; Anne Marie Gillespie; Peder E Z Larson; H Artee Luchman; Joseph F Costello; Russell O Pieper; Sabrina M Ronen
Journal:  Neuro Oncol       Date:  2021-09-01       Impact factor: 13.029

Review 6.  From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.

Authors:  Xueyuan Sun; Sevin Turcan
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

7.  Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.

Authors:  Pavithra Viswanath; Marina Radoul; Jose Luis Izquierdo-Garcia; Hema Artee Luchman; J Gregory Cairncross; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen
Journal:  Cancer Metab       Date:  2018-04-03

Review 8.  IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.

Authors:  Sue Han; Yang Liu; Sabrina J Cai; Mingyu Qian; Jianyi Ding; Mioara Larion; Mark R Gilbert; Chunzhang Yang
Journal:  Br J Cancer       Date:  2020-04-15       Impact factor: 7.640

9.  Expression of SCD and FADS2 Is Lower in the Necrotic Core and Growing Tumor Area than in the Peritumoral Area of Glioblastoma Multiforme.

Authors:  Jan Korbecki; Klaudyna Kojder; Dariusz Jeżewski; Donata Simińska; Maciej Tarnowski; Patrycja Kopytko; Krzysztof Safranow; Izabela Gutowska; Marta Goschorska; Agnieszka Kolasa-Wołosiuk; Barbara Wiszniewska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Biomolecules       Date:  2020-05-07

10.  MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.

Authors:  Abigail R Molloy; Chloé Najac; Pavithra Viswanath; Aliya Lakhani; Elavarasan Subramani; Georgios Batsios; Marina Radoul; Anne Marie Gillespie; Russell O Pieper; Sabrina M Ronen
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.